HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,125-2,136 of 4,505
Drug study icon
CompletedNCT01655680

ABT-126 for schizophrenia

What is this study about?

Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Anaheim
SchizophreniaMedication studyAges 20–65
Countries
United States, United Kingdom, Russia
Sponsor
AbbVie (prior sponsor, Abbott)
Drug study icon
CompletedNCT00396565

Effectiveness of Effectiveness and Safety of ER OROS Paliperidone in schizophrenia

What is this study about?

Researchers compared ER OROS paliperidone, placebo and Olanzapine to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Aizu-Wakamatsu
SchizophreniaMedication studyAges 20+
Countries
Japan
Sponsor
Janssen Pharmaceutical K.K.
Drug study icon
CompletedNCT01192880

Bitopertin for schizophrenia

Official study title

A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period

This study has finished and is no longer accepting participants.

Multiple locations, including Costa Mesa
SchizophreniaMedication studyAges 18+
Countries
United States, Bulgaria, China, + 4 others
Sponsor
Hoffmann-La Roche
Drug study icon
CompletedNCT01010776

Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in schizophrenia

Official study title

A Study to Evaluate Switching From Risperidone to Paliperidone ER (Extended Release) in the Treatment of Stable But Symptomatic Schizophrenia Outpatients: Patients Satisfaction and Quality of Life

This study has finished and is no longer accepting participants.

Multiple locations, including Belo Horizonte
SchizophreniaMedication studyAges 18–60
Countries
Brazil
Sponsor
Janssen-Cilag Farmaceutica Ltda.
Drug study icon
CompletedNCT03713658

Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Official study title

A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda

This study has finished and is no longer accepting participants.

Multiple locations, including Kigali
SchizophreniaMedication studyAges 18–70
Countries
Rwanda
Sponsor
Janssen Research & Development, LLC
Drug study icon
TerminatedNCT01670071

Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function for schizophrenia

Official study title

A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia

This study ended early.

Multiple locations, including Bali Township, Taipei County
SchizophreniaMedication studyAges 20–60
Countries
Taiwan
Sponsor
Johnson & Johnson Taiwan Ltd
Drug study icon
CompletedNCT01730768

Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

Official study title

A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

This study has finished and is no longer accepting participants.

Multiple locations, including Garden Grove
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
Novartis Pharmaceuticals

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.